Method of providing safe administration of adenoviral vectors encoding a zika virus antigen

Abstract

Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.

It is claimed: 
     
         1 . A method for generating an immune response against a Zika virus in a human subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising adenoviral vectors comprising a nucleic acid sequence encoding a Zika virus antigen, wherein the Zika virus antigen comprises the amino acid sequence of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein about 1×10 11  adenoviral vectors are administered in a single dose to the human subject in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition is administered via an intramuscular injection to the subject in need thereof. 
     
     
         3 . The method of  claim 1 , wherein the immune response is a protective immune response against a Zika virus. 
     
     
         4 . The method of  claim 1 , wherein the adenoviral vectors are of the Ad26 serotype. 
     
     
         5 . A method for preventing a Zika virus infection or the progression of a Zika virus infection in a human subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising adenoviral vectors comprising a nucleic acid sequence encoding a Zika virus antigen, wherein the Zika virus antigen comprises the amino acid sequence of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein about 1×10 11  adenoviral vectors are administered in a single dose to the human subject in need thereof. 
     
     
         6 . The method of  claim 5 , wherein the pharmaceutical composition is administered via an intramuscular injection to the subject in need thereof. 
     
     
         7 . The method of  claim 5 , wherein the adenoviral vectors are of the Ad26 serotype.